slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 65,371-65,400
Pages 2,605
Rows per page 30
Component
65,371-65,400 of 78,138
07
The chart compares quarterly container volumes between 2022 and 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
08
The chart compares 2022 vs 2023 quarterly container volumes.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
09
The chart shows quarterly container volume (FEU) for 2022 vs 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
10
The chart shows quarterly operating income for 2022 and 2023, with Q4 2023 highlighted as a range.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
04
The slide uses a dual-track timeline (Cell Therapy and Drug Discovery) to show company evolution.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
06
The central hub is 'Accelerate Product Development', surrounded by four strategic pillars, each with a corresponding icon.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The chart shows a cumulative growth trend of partner milestones over time, with logos placed in vertical columns representing years.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
09
Uses a stacked area chart to represent revenue components (instruments, milestones, sales-based payments) over time.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
11
The chart uses a stacked bar format to distinguish between pre-commercial and commercial revenue components.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
The slide uses a timeline-based comparison to highlight time savings (6+ months vs 1-2 months).MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
05
The chart shows revenue growth across three regions (Americas, EMEA, Asia) over three time points (2010, 2018, 2023).Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · What IsLoop · Benchmark Gap1 hit
06
The slide uses a Gantt-style layout to map clinical phases to specific time periods.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Golden Circle1 hit
12
The slide presents 10 distinct bar charts comparing Control, DA, DA+DPP4i, and DPP4i groups, with statistical significance markers.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
07
The slide uses a combination of a biological mechanism diagram and a pharmacokinetic line chart to prove efficacy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
09
The chart demonstrates that PrimeC aligns the peak concentrations of two different drugs, which is the core value proposition of their formulation technology.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
17
The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
19
The chart visualizes the reduction in point loss, highlighting the efficacy of PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
20
The slide uses a human silhouette to categorize ALS symptoms into four domains, then presents bar charts for each domain comparing treatment vs placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
21
The chart highlights a 17.2% attenuation in the decline of SVC scores for the PrimeC group compared to placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
25
The slide presents clinical biomarker data comparing control vs AD groups across 6 different markers, using Mann-Whitney U tests for significance.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
31
The chart shows a clear divergence between the treatment and placebo arms over time, with a 29.2% difference at the 180-day mark.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
32
The chart shows a divergence in SVC decline between the treatment and placebo groups over time.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
12
The chart illustrates the bridge between two balance sheet dates.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
13
The chart highlights Flagstar's positive growth (+6.79%) against negative trends in the broader US banking sector.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
16
The chart highlights NYCB's generally lower non-performing loan ratios compared to the broader market index over the observed period.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
17
The chart highlights a significant spike in charge-offs for the S&P index during the 2008-2012 period compared to NYCB.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
18
The chart uses a dashed line to represent the peer median of 0.55%.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
22
The slide displays a pie chart of loan distribution and a list of portfolio highlights including yield, historical losses, and criticized loan increases.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
29
Includes a footnote referencing page 30 for additional Warehouse information.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit
37
The chart illustrates the transition from $2,088M in 2023 to $2,353M in 2024.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Guidance1 hit